Showing results (51-60 of 105) with videos related to

Sort By:
Pageof 11
Brain Tumor Pathology|May 21, 2026
Dual TERT promoter mutations in glioblastoma, IDH-wildtype: a case report with preclinical investigationsYohei Miyake, Kensuke Tateishi, Hinako Okagawa, et al.
Thrombosis Research|January 27, 2023
Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomasKazuhiro Ando, Manabu Natsumeda, Masahide Kawamura, et al.
Acta Neuropathologica Communications|November 29, 2025
Targeting distinct amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomasShigeo Ohba, Akiyoshi Hirayama, Takao Teranishi, et al.
European Journal of Neurology|June 23, 2023
Progressive conus medullaris lesions are suggestive of intravascular large B-cell lymphomaSho Kitahara, Masato Kanazawa, Manabu Natsumeda, et al.
Expert Review of Anticancer Therapy|June 24, 2026
The dual role of Schlafen11 in brain tumors: Jekyll and HydeManabu Natsumeda, Masayasu Okada, Satoshi Nakata, et al.
Stem Cells (Dayton, Ohio)|April 20, 2016
Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating CellsYoshihiro Tsukamoto, Naoki Ohtsu, Smile Echizenya, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|January 12, 2019
Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for high-MYC medulloblastomaManabu Natsumeda, Yang Liu, Satoshi Nakata, et al.
Journal of Neurosurgery. Case Lessons|March 23, 2026
Molecularly distinct collision tumor consisting of meningothelial meningioma and glioblastoma, IDH-wildtype: illustrative caseAsuka Ueno, Yoshihiro Tsukamoto, Kiichi Sakai, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|January 3, 2013
Epstein-Barr virus-associated primary central nervous system cytotoxic T-cell lymphomaRyosuke Ogura, Hiroshi Aoki, Manabu Natsumeda, et al.
JCI Insight|November 22, 2024
CRISPR/CasRx suppresses KRAS-induced brain arteriovenous malformation developed in postnatal brain endothelial cells in miceShoji Saito, Yuka Nakamura, Satoshi Miyashita, et al.
Pageof 11